**INFORMATION DISCLOSURE STATEMENT**

Applicant : Whitehead et al.
App. No : 10/719,547
Filed : November 21, 2003
For : DEVELOPMENT OF MUTATIONS
USEFUL FOR ATTENUATING
DENGUE VIRUSES AND CHIMERIC
DENGUE VIRUSES
Examiner : Chen, Stacy Brown
Art Unit : 1648

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Dear Sir:

Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing 11 references to be considered by the Examiner. Also enclosed are 11 foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required. The Commissioner is hereby authorized to charge any additional fees which may be required or to credit any overpayment to Account No. 11-1410.

Respectfully submitted,
KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 9/28/05

By: 
Nancy W. Vensko
Registration No. 36,298
Attorney of Record
Customer No. 45,311
(805) 547-5580

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Multiple sheets used when necessary)

SHEET 1 OF 2

Application No.	10/719,547
Filing Date	November 21, 2003
First Named Inventor	Whitehead, Stephen S.
Art Unit	1648
Examiner	Chen, Stacy Brown
Attorney Docket No.	NIH214.001C1

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	1	BLANEY, Jr. J.E. et al. (2001) "Chemical mutagenesis of dengue virus type 4 yields mutant viruses which are temperature sensitive in vero cells or human liver cells and attenuated in mice" <i>J. Virol.</i> 75:9731-9740.	
	2	BLANEY, Jr. J.E. et al. (2002) "Genetic basis of attenuation of dengue virus type 4 small plaque mutants with restricted replication in suckling mice and an SCID mice transplanted with human liver cells" <i>Virology</i> 300:125-139.	
	3	BLANEY, Jr. J.E. et al. (2003) "Mutations which enhance the replication of dengue virus type 4 and an antigenic chimeric Dengue virus type 2/4 vaccine candidate in Vero cells" <i>Vaccine</i> 21:4317-4327.	
	4	BLANEY, Jr. J.E. et al. (2003) "Temperature sensitive mutations in the genes encoding the ns1, ns2a, and ns5 nonstructural proteins of dengue virus type 4 restrict replication in the brains of mice" <i>Arch. Virol.</i> 148:999-1006.	
	5	BLANEY, Jr. J.E. et al. (2004) "Genetically modified, live attenuated dengue virus type 3 vaccine candidates" <i>Am. J. Trop. Med. Hyg.</i> 71:811-821	
	6	BLANEY, Jr. J.E. et al. (2005) "Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in Rhesus monkeys" <i>J. Virol.</i> 79:5516-5528.	
	7	HANLEY, K.A. et al. (2002) "Paired charge-to-alanine mutagenesis of dengue virus type 4 ns5 generates mutants with temperature-sensitive, host range, and mouse attenuation phenotypes" <i>J. Virol.</i> 76:525-531.	
	8	HANLEY, K.A. et al. (2003) "A trade-off in replication in mosquito versus mammalian systems conferred by a point mutation in the ns4b protein of dengue virus type 4" <i>Virology</i> 312:222-232.	
	9	HANLEY, K.A. et al. (2004) "Introduction of mutations into the non-structural genes or 3' untranslated region of an attenuated dengue virus type 4 vaccine candidate further decreases replication in rhesus monkeys while retaining protective immunity" <i>Vaccine</i> 22:3440-3448.	
	10	WHITEHEAD, S.S. et al. (2003) "A live attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3' untranslated region is highly attenuated and immunogenic in monkeys" <i>J. Virol.</i> 77:1653-1657.	

Examiner Signature

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application No.	10/719,547
Filing Date	November 21, 2003
First Named Inventor	Whitehead, Stephen S.
Art Unit	1648
Examiner	Chen, Stacy Brown
Attorney Docket No.	NIH214.001C1

(Multiple sheets used when necessary)

SHEET 2 OF 2

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	11	WHITEHEAD, S.S. et al. (2003) "Substitution of the structural genes of dengue virus type 4 with those of type 2 results in chimeric vaccine candidates which are attenuated for mosquitoes, mice, and rhesus monkeys" <i>Vaccine</i> 21:4307-4316.	

1957043:vr
092705

Examiner Signature

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T¹ - Place a check mark in this area when an English language Translation is attached.